United States - English - NLM (National Library of Medicine)

blenheim pharmacal, inc. - famotidine (unii: 5qzo15j2z8) (famotidine - unii:5qzo15j2z8) - famotidine 20 mg - famotidine is indicated in: - short term treatment of active duodenal ulcer. most adult patients heal within 4 weeks; there is rarely reason to use famotidine at full dosage for longer than 6 to 8 weeks. studies have not assessed the safety of famotidine in uncomplicated active duodenal ulcer for periods of more than eight weeks. - maintenance therapy for duodenal ulcer patients at reduced dosage after healing of an active ulcer. controlled studies in adults have not extended beyond one year. - short term treatment of active benign gastric ulcer. most adult patients heal within 6 weeks. studies have not assessed the safety or efficacy of famotidine in uncomplicated active benign gastric ulcer for periods of more than 8 weeks. - short term treatment of gastroesophageal reflux disease (gerd). famotidine is indicated for short term treatment of patients with symptoms of gerd (see clinical pharmacology in adults, clinical studies ). famotidine is also i

United States - English - NLM (National Library of Medicine)

aidarex pharmaceuticals llc - famotidine (unii: 5qzo15j2z8) (famotidine - unii:5qzo15j2z8) - famotidine 20 mg - famotidine is indicated in: - short term treatment of active duodenal ulcer. most adult patients heal within 4 weeks; there is rarely reason to use famotidine at full dosage for longer than 6 to 8 weeks. studies have not assessed the safety of famotidine in uncomplicated active duodenal ulcer for periods of more than eight weeks. - maintenance therapy for duodenal ulcer patients at reduced dosage after healing of an active ulcer. controlled studies in adults have not extended beyond one year. - short term treatment of active benign gastric ulcer. most adult patients heal within 6 weeks. studies have not assessed the safety or efficacy of famotidine in uncomplicated active benign gastric ulcer for periods of more than 8 weeks. - short term treatment of gastroesophageal reflux disease (gerd). famotidine is indicated for short term treatment of patients with symptoms of gerd (see clinical pharmacology in adults, clinical studies ). famotidine is also indicated for the short term treatment of esophag

United States - English - NLM (National Library of Medicine)

dispensing solutions, inc. - famotidine (unii: 5qzo15j2z8) (famotidine - unii:5qzo15j2z8) - famotidine 40 mg - famotidine is indicated in: - short term treatment of active duodenal ulcer. most adult patients heal within 4 weeks; there is rarely reason to use famotidine at full dosage for longer than 6 to 8 weeks. studies have not assessed the safety of famotidine in uncomplicated active duodenal ulcer for periods of more than eight weeks. - maintenance therapy for duodenal ulcer patients at reduced dosage after healing of an active ulcer. controlled studies in adults have not extended beyond one year. - short term treatment of active benign gastric ulcer. most adult patients heal within 6 weeks. studies have not assessed the safety or efficacy of famotidine in uncomplicated active benign gastric ulcer for periods of more than 8 weeks. - short term treatment of gastroesophageal reflux disease (gerd). famotidine is indicated for short term treatment of patients with symptoms of gerd (see clinical pharmacology in adults, clinical studies ). famotidine is also indicated for the short term treatment of esophag

United States - English - NLM (National Library of Medicine)

carlsbad technology, inc - famotidine (unii: 5qzo15j2z8) (famotidine - unii:5qzo15j2z8) - famotidine 20 mg - famotidine tablets are indicated in adult and pediatric patients 40 kg and above for the treatment of: • active duodenal ulcer. • active gastric ulcer. • symptomatic non-erosive gastroesophageal reflux disease (gerd). • erosive esophagitis due to gerd, diagnosed by biopsy. famotidine tablets are indicated in adults for the: • treatment of pathological hypersecretory conditions (e.g., zollinger- ellison syndrome, multiple endocrine neoplasias). • reduction of the risk of duodenal ulcer recurrence. famotidine is contraindicated in patients with a history of serious hypersensitivity reactions (e.g., anaphylaxis) to famotidine or other histamine-2 (h 2 ) receptor antagonists. 8.1 pregnancy risk summary available data with h 2 -receptor antagonists, including famotidine, in pregnant women are insufficient to establish a drug-associated risk of major birth defects, miscarriage or adverse maternal or fetal outcomes. in animal reproduction

United States - English - NLM (National Library of Medicine)

nucare pharmaceuticals,inc. - famotidine (unii: 5qzo15j2z8) (famotidine - unii:5qzo15j2z8) - famotidine 20 mg - famotidine tablets are indicated in: 1. short-term treatment of active duodenal ulcer most adult patients heal within 4 weeks; there is rarely reason to use famotidine at full dosage for longer than 6 to 8 weeks. studies have not assessed the safety of famotidine in uncomplicated active duodenal ulcer for periods of more than eight weeks. 2. maintenance therapy for duodenal ulcer patients at reduced dosage after healing of an active ulcer controlled studies in adults have not extended beyond one year. 3. short-term treatment of active benign gastric ulcer most adult patients heal within 6 weeks. studies have not assessed the safety or efficacy of famotidine in uncomplicated active benign gastric ulcer for periods of more than 8 weeks. 4. short-term treatment of gastroesophageal reflux disease (gerd) famotidine tablets are indicated for short-term treatment of patients with symptoms of gerd (see clinical pharmacology in adults , clinical studies ). famotidine tablets are also indicate

United Kingdom - English - MHRA (Medicines & Healthcare Products Regulatory Agency)

tillomed laboratories ltd - famotidine - oral tablet - 20mg

United Kingdom - English - MHRA (Medicines & Healthcare Products Regulatory Agency)

tillomed laboratories ltd - famotidine - oral tablet - 40mg

United States - English - NLM (National Library of Medicine)

h.j. harkins company, inc. - famotidine (unii: 5qzo15j2z8) (famotidine - unii:5qzo15j2z8) - famotidine 40 mg - famotidine is indicated in: - short term treatment of active duodenal ulcer. most adult patients heal within 4 weeks; there is rarely reason to use famotidine at full dosage for longer than 6 to 8 weeks. studies have not assessed the safety of famotidine in uncomplicated active duodenal ulcer for periods of more than eight weeks. - maintenance therapy for duodenal ulcer patients at reduced dosage after healing of an active ulcer. controlled studies in adults have not extended beyond one year. - short term treatment of active benign gastric ulcer. most adult patients heal within 6 weeks. studies have not assessed the safety or efficacy of famotidine in uncomplicated active benign gastric ulcer for periods of more than 8 weeks. - short term treatment of gastroesophageal reflux disease (gerd). famotidine is indicated for short term treatment of patients with symptoms of gerd (see clinical pharmacology in adults, clinical studies ). famotidine is also indicated for the short term treatment of esophag

Canada - English - Health Canada

mint pharmaceuticals inc - famotidine - tablet - 20mg - famotidine 20mg

Canada - English - Health Canada

mint pharmaceuticals inc - famotidine - tablet - 40mg - famotidine 40mg